scholarly journals Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Kensuke Abe ◽  
Taku Obara ◽  
Satomi Kamio ◽  
Asahi Kondo ◽  
Junji Imamura ◽  
...  
Keyword(s):  
Renal Function ◽  
Observational Study ◽  
Renal Dysfunction ◽  
Tenofovir Disoproxil Fumarate ◽  
Single Center ◽  
Long Term Treatment ◽  
Tenofovir Alafenamide ◽  
Hiv 1 ◽  
Single Center Observational Study

Abstract Background Tenofovir disoproxil fumarate (TDF) has a strong antiviral effect, but TDF is known to cause renal dysfunction. Therefore, we are investigating preventing renal dysfunction by replacing TDF with tenofovir alafenamide fumarate (TAF), which is known to be relatively safe to the kidneys. However, the changes in renal function under long-term use of TAF are not known. In this study, we evaluated renal function in Japanese HIV-1-positive patients switching to TAF after long-term treatment with TDF. Methods A single-center observational study was conducted in Japanese HIV-1-positive patients. TDF was switched to TAF after at least 48 weeks of the treatment so we could evaluate the long-term use of TDF. The primary endpoint was the estimated glomerular filtration rate (eGFR) at 144 weeks of TAF administration. In addition, we predicted the factors that would lead to changes in eGFR after long-term use of TAF. Results Of the 125 HIV-1-positive patients who were prescribed TAF at our hospital during the study period, 70 fulfilled the study criteria. The eGFR at the time of switching from TDF to TAF was 81.4 ± 21.1 mL/min/1.73 m2. eGFR improved significantly after 12 weeks of taking TAF but significantly decreased at 96 and 144 weeks. The factors significantly correlated with the decrease in eGFR at 144 weeks on TAF were eGFR and weight at the start of TAF. Conclusions In this study, it was confirmed that switching to TAF was effective for Japanese HIV-1-positive patients who had been taking TDF for a long period of time and had a reduced eGFR. It was also found that the transition status depended on the eGFR and weight at the time of switch. Since HIV-1-positive patients in Japan are expected to continue taking TAF for a long time, renal function and body weight should be carefully monitored.

scholarly journals Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate

2021 ◽  
Author(s):  
Kensuke Abe ◽  
Taku Obara ◽  
Satomi Kamio ◽  
Asahi Kondo ◽  
Junji Imamura ◽  
...  
Keyword(s):  
Renal Function ◽  
Renal Dysfunction ◽  
Tenofovir Disoproxil Fumarate ◽  
Antiviral Effect ◽  
Term Treatment ◽  
Long Term Treatment ◽  
The Difference ◽  
Tenofovir Alafenamide ◽  
Hiv 1

Abstract BACKGROUND Tenofovir disoproxil fumarate (TDF) has a strong antiviral effect, but TDF is known to cause renal dysfunction. Therefore, we are investigating preventing renal dysfunction by replacing TDF with tenofovir alafenamide fumarate (TAF), which is known to be relatively safe to the kidneys. However, the changes in renal function under long-term use of TAF are not known. In this study, we evaluated renal function in Japanese HIV-1-positive patients switching to TAF after long-term treatment with TDF.METHODS A single-center observational study was conducted in Japanese HIV-1-positive patients. TDF was switched to TAF after at least 48 weeks of treatment so we could evaluate the long-term use of TDF. The primary endpoint was the estimated glomerular filtration rate (eGFR) at 144 weeks of TAF administration. In addition, we predicted the factors that would lead to changes in eGFR after long-term use of TAF.RESULTS Of the 125 HIV-1-positive patients who were prescribed TAF at our hospital during the study period, 70 fulfilled the study criteria. The eGFR at the time of switching from TDF to TAF was 81.4 ± 21.1 mL/min/1.73 m2. eGFR improved significantly after 12 weeks of taking TAF but significantly decreased at 96 and 144 weeks. At 144 weeks of taking TAF, the factors significantly correlated with the difference in eGFR from baseline were the difference in eGFR at 48 weeks of taking TAF and age at the start of TAF.CONCLUSIONS In this study, Japanese HIV-1-positive patients who had been taking TDF for a long period of time showed a decrease in eGFR after switching to long-term use of TAF. Japanese HIV-1-positive patients are expected to take TAF for a long time. Depending on age, laboratory values related to renal function need to be monitored carefully.

Long‐term efficacy of add‐on lacosamide treatment in children and adolescents with refractory epilepsies: A single‐center observational study

Epilepsia ◽  
2018 ◽  
Vol 59 (5) ◽  
pp. 1004-1010 ◽  
Author(s):  
Anna Rosati ◽  
Lucrezia Ilvento ◽  
Riccardo Rizzi ◽  
Viola Doccini ◽  
Maria Carmela Leo ◽  
...  
Keyword(s):  
Observational Study ◽  
Children And Adolescents ◽  
Single Center ◽  
Term Efficacy ◽  
Single Center Observational Study

scholarly journals Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Wenxin Bai ◽  
Xinyang Zhang ◽  
Si Sun ◽  
Qiaohong Wang ◽  
Congcong Li ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Observational Study ◽  
Renal Dysfunction ◽  
Adverse Reactions ◽  
Low Molecular Weight ◽  
Single Center ◽  
Low Molecular Weight Heparins ◽  
Enoxaparin Group ◽  
Local Allergy ◽  
Single Center Observational Study

Abstract Objective To compare three commonly used low-molecular-weight heparins (LWMHs) in the treatment of recurrent spontaneous abortion (RSA) by evaluating the anti-Xa peak levels and adverse reactions. Methods In this single-center, observational study, we enrolled 310 patients with RSA in whom anti-Xa levels were measured during pregnancy. Patients were divided into three groups according to the LMWH they used: the nadroparin group, enoxaparin group and dalteparin group. We compared the peak anti-Xa levels and the coagulation status of each group, and analyzed the incidence of adverse reactions, including local allergy, liver and renal dysfunction, and the impact on platelet. Results Patients in the enoxaparin group had a higher anti-Xa peak level than those in the nadroparin group (0.80 ± 0.22 IU/ml vs. 0.61 ± 0.24 IU/ml; P <  0.0001), although most patients in the three groups reached the target concentration of anti-Xa. Furthermore, patients in the enoxaparin group had a more stable anti-Xa levels during pregnancy. In addition, patients in the nadroparin group had a higher rate of local allergy than those in the enoxaparin group (60.5% vs. 42.5%; P = 0.004) and those in the dalteparin group (60.5% vs. 33.3%; P = 0.002). Further examination by the type of local allergy indicated a dramatic difference in pruritus and induration between the nadroparin group and the other two groups. No difference was found in the incidence of liver and renal dysfunction and thrombocytopenia. Conclusion Compared with nadroparin and daltepatin, enoxaparin showed a better performance regarding anti-Xa levels and the incidence of adverse reactions in the treatment of RSA.

Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up

2012 ◽  
Vol 67 (4) ◽  
pp. 617-622 ◽  
Author(s):  
Giuseppe Cianchini ◽  
Francesca Lupi ◽  
Cinzia Masini ◽  
Rosamaria Corona ◽  
Pietro Puddu ◽  
...  
Keyword(s):  
Observational Study ◽  
Single Center ◽  
Long Term Follow Up ◽  
Single Center Observational Study
Sign in / Sign up

Export Citation Format

Share Document